{
  "docId": "019de076-6120-7265-9083-1f4de3ff0bf7",
  "docSlug": "b6cd6d5e2a349d701bc6db22946ed621",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 52,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 20,
  "notes": "The table uses a green/white color coding to highlight positive attributes (Yes) versus negative ones (No).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-6120-7265-9083-1f4de3ff0bf7/11",
  "deckHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7",
  "deckJsonHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7.json",
  "deckAnchorHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.045,
        "w": 0.895,
        "x": 0.076,
        "y": 0.865
      },
      "kind": "disclaimer",
      "text": "No head-to-head clinical studies have been conducted for currently approved or investigational therapies versus NVL-520. Clinical investigation of NVL-520 is ongoing.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4fefa5b8-f7e1-4f16-979b-3ab3a570ee6f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.585,
        "w": 0.862,
        "x": 0.069,
        "y": 0.25
      },
      "kind": "table",
      "text": "Comparison matrix of NVL-520 vs Crizotinib, Entrectinib, Lorlatinib, and Repotrectinib across Wild Type ROS1, G2032R ROS1, TRKB Sparing, and CNS Activity.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "babee23b-94be-43ca-ab80-0a5e3b7ae286",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.026,
        "w": 0.535,
        "x": 0.076,
        "y": 0.188
      },
      "kind": "title",
      "text": "Differentiated Product Candidate for ROS1-positive NSCLC Patients",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9a3b4510-01b9-49ff-80e7-a37b6525ce9d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.063,
        "w": 0.191,
        "x": 0.076,
        "y": 0.115
      },
      "kind": "title",
      "text": "NVL-520",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "791a2984-edbb-449d-822e-341db1b553af",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "6cf09fc5-9dce-418f-a8dd-8b996b191e7e",
      "evidence": "Comparison matrix of NVL-520 vs Crizotinib, Entrectinib, Lorlatinib, and Repotrectinib across Wild Type ROS1, G2032R ROS1, TRKB Sparing, and CNS Activity.",
      "confidence": 0.6
    }
  ],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "c7578636-88ac-4d20-b028-670a55122749",
      "evidence": "The slide uses a structured table to compare the subject product against competitors across specific criteria.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 12,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "5e62d3b3-7d2f-4957-9be3-165db6a30ea2",
      "evidence": "Slides 7-12 discuss the limitations of current treatments and the need for new solutions.",
      "position": 0,
      "objective": "What are the consequences of not addressing drug resistance in cancer treatment?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}